| Literature DB >> 24506545 |
Dorota Jesionek-Kupnicka1, Malgorzata Szybka, Beata Malachowska, Wojciech Fendler, Piotr Potemski, Sylwester Piaskowski, Dariusz Jaskolski, Wielislaw Papierz, Wieslaw Skowronski, Waldemar Och, Radzislaw Kordek, Izabela Zawlik.
Abstract
Reduced expression of TP53 by promoter methylation has been reported in several neoplasms. It remains unclear whether TP53 promoter methylation is associated with reduced transcriptional and protein expression in glioblastoma (GB). The aim of our work was to study the impact of TP53 methylation and mutations on TP53 mRNA level and protein expression in 42 molecularly characterized primary GB tumors. We also evaluate the impact of all molecular alterations on the overall patient survival. The frequency of TP53 promoter methylation was found in 21.4%. To the best of our knowledge, this is the first report showing such high frequency of TP53 promoter methylation in primary GB. There was no relation between TP53 promoter methylation and TP53 mRNA level (p=0.5722) and between TP53 promoter methylation and TP53 protein expression (p=0.2045). No significant associations were found between TP53 mRNA expression and mutation of TP53 gene (p=0.9076). However, significant association between TP53 mutation and TP53 protein expression was found (p=0.0016). Our data suggest that in primary GB TP53 promoter methylation does not play a role in silencing of TP53 transcriptional and protein expression and is probably regulated by other genetic and epigenetic mechanisms associated with genes involved in the TP53 pathway.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24506545 PMCID: PMC3967380 DOI: 10.1089/dna.2013.2201
Source DB: PubMed Journal: DNA Cell Biol ISSN: 1044-5498 Impact factor: 3.311